Analysts Issue Forecasts for SXTP Q1 Earnings

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) – Ascendiant Capital Markets issued their Q1 2026 earnings per share (EPS) estimates for 60 Degrees Pharmaceuticals in a report issued on Thursday, April 9th. Ascendiant Capital Markets analyst L. Ward expects that the company will post earnings of ($0.99) per share for the quarter. Ascendiant Capital Markets currently has a “Buy” rating and a $4.20 price target on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($5.09) per share. Ascendiant Capital Markets also issued estimates for 60 Degrees Pharmaceuticals’ Q2 2026 earnings at ($0.78) EPS, Q3 2026 earnings at ($0.79) EPS, Q4 2026 earnings at ($0.83) EPS and FY2026 earnings at ($3.18) EPS.

Several other equities analysts have also commented on SXTP. HC Wainwright upped their target price on 60 Degrees Pharmaceuticals from $6.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. Wall Street Zen downgraded 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, 60 Degrees Pharmaceuticals has an average rating of “Hold” and an average target price of $14.10.

60 Degrees Pharmaceuticals Stock Up 14.4%

Shares of 60 Degrees Pharmaceuticals stock opened at $2.22 on Wednesday. The firm has a market cap of $5.86 million, a P/E ratio of -0.16 and a beta of 3.27. 60 Degrees Pharmaceuticals has a fifty-two week low of $1.29 and a fifty-two week high of $17.68. The business has a 50-day moving average price of $2.55 and a 200 day moving average price of $3.63.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.